Downregulation of GPX3 expression by promoter hypermethylation has been reported in 71.4% of esophageal squamous cell carcinoma, 83% of gastric cancer and 90% of prostate cancer [17,26,27], indicating its possible suppression by epigenetic change in ccRCC. Here, GPX3 is linked to prostate cancer.